Astrazeneca Share Price (AZN)

[ADVERT]

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Astrazeneca Plc	LSE:AZN	London	Ordinary Share	GB0009895292	ORD SHS $0.25

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	111.00	1.23%	9,114.00	689,030	13:53:42

Bid Price		Offer Price	High Price	Low Price	Open Price
9,113.00		9,115.00	9,149.00	9,018.00	9,060.00

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	19,468.19	2,864.24	178.47	51.4	141,186

Last Trade Time	Trade Type	Trade Size	Trade Price	Currency
13:53:31	O	10	9,114.535	GBX

Related Shares
Glaxosmithkline (GSK), Hikma Pharmaceuticals (HIK), Motif Bio (MTFB), Bermele (BERM)

Astrazeneca (AZN) Latest News

Astrazeneca News

Date	Time	Source	Headline
25/10/2021	08:16	ALNC	AstraZeneca cancer drug trial shows improved overall survival rate
25/10/2021	07:46	DJN	AstraZeneca's Imfinzi-Chemotherapy Combination Improved Biliary Tract..
25/10/2021	07:00	UKREG	AstraZeneca PLC Imfinzi improved survival in biliary tract cancer
18/10/2021	09:08	ALNC	TOP NEWS: AstraZeneca urges shareholders to veto TRC mini-tender offer
18/10/2021	07:50	DJN	AstraZeneca Recommends Shareholders Reject TRC Capital Mini-Tender Bid
18/10/2021	07:00	UKREG	AstraZeneca PLC AZ recommends ADS holders reject mini-tender offer
15/10/2021	13:05	DJN	AstraZeneca Says Study in Liver Cancer Meets Objective
15/10/2021	08:34	ALNC	AstraZeneca says Imfinzi combination drug boosts liver cancer survival
15/10/2021	07:49	DJN	AstraZeneca Says Combination of Tremelimumab and Imfinzi Antibodies Boosted..
15/10/2021	07:00	UKREG	AstraZeneca PLC Imfinzi & tremelimumab improved OS in liver cancer

More Astrazeneca News

Astrazeneca Investors Astrazeneca Takeover Rumours

Astrazeneca (AZN) Share Charts 1 Year Astrazeneca Chart
1 Month Astrazeneca Chart	Intraday Astrazeneca Chart

Smart Money! AZN is a large holding in the following funds:
Fund	Percentage of Fund	Last Updated
EP GLOBAL OPPORTUNITIES TRUST PLC	2.30%	2020-11-30
BLACKROCK INCOME AND GROWTH INVESTMENT TRUST PLC	6.90%	2021-09-30
BMO CAPITAL AND INCOME INVESTMENT TRUST PLC	4.30%	2021-09-30
JUPITER UK GROWTH INVESTMENT TRUST PLC	3.70%	2021-10-26
JPMORGAN CLAVERHOUSE INVESTMENT TRUST PLC	6.00%	2021-09-30

Astrazeneca (AZN) Discussions and Chat

Astrazeneca Forums and Chat

Date	Time	Title	Posts
26/10/2021	17:57	AstraZeneca	5,036
20/9/2021	15:45	INDIA'S COVID DEATH RATE IS 278 PER 1 MILLION..UK'S IS 1876..THINK ABOUT IT	1
15/9/2021	12:17	Eu	2
03/9/2021	16:44	EU and AZN	3
24/6/2021	16:39	ASTRAZENECA, MSD PROSTATE CANCER DRUG GETS CHINA GREEN LIGHT	1

Add a New Thread

Astrazeneca (AZN) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
12:53:32	9,114.54	10	911.45	O
12:53:06	9,114.00	29	2,643.06	AT
12:52:45	9,109.10	1,000	91,091.04	O
12:52:41	9,113.00	90	8,201.70	AT
12:52:22	9,115.00	34	3,099.10	AT

View all Astrazeneca trades in real-time

Astrazeneca (AZN) Top Chat Posts

Date	Subject
27/10/2021 09:20	Astrazeneca Daily Update: Astrazeneca Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AZN. The last closing price for Astrazeneca was 9,003p. Astrazeneca Plc has a 4 week average price of 8,565p and a 12 week average price of 8,029p. The 1 year high share price is 9,149p while the 1 year low share price is currently 6,736p. There are currently 1,549,116,129 shares in issue and the average daily traded volume is 1,177,909 shares. The market capitalisation of Astrazeneca Plc is £141,573,723,029.31. Read Full Thread Reply
21/10/2021 13:51	philanderer: J.P.Morgan keeps AstraZeneca as 'top pick' on growth outlook, undervaluation (Sharecast News) - AstraZeneca's growth outlook is the best in its sector and was not yet reflected in its share price, analysts at JP Morgan said following a 'deep dive' into the drug maker's financials. Hence their decision to keep the shares as their 'top pick' in the sector. In local currency terms, the broker estimated that the company's core earnings per share were set to grow by 33%, 27% and 23% between 2021-23 - excluding its Covid-19 vaccine. Subsequently, EPS was seen growing at a compound annual rate of growth of 9% over 2023-26. Furthermore, Astra was only trading on 14.5 times' its estimated core EPS for 2023, against its sector trading on 16.5 Yet the expected rate of growth in the drugmaker's core EPS across 2023-26 in compound annual terms was expected to be four percentage points higher thanks to its comparatively young on-market portfolio and deep late stage pipeline. "Given our forecast for a strong growth outlook, and the compelling valuation, we remain Overweight, with Astra remaining a top pick in the sector." Read Full Thread Follow Reply
19/10/2021 08:21	arja: nothing helping the share price at present as it drifts slowly down . Read Full Thread Follow Reply
11/10/2021 13:46	beckers2008: AstraZeneca : Deutsche Bank Boosts AstraZeneca's PT, Keeps PT 10/11/2021 \| 01:23pm BST (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) on Monday raised its price target on AstraZeneca (AZN.L, AZN.ST) to 105 pounds sterling ($143.19) from 102 pounds and maintained its buy rating. The Anglo-Swedish pharmaceutical company's shares increased marginally on Monday midday. Read Full Thread Follow Reply
29/9/2021 15:39	arja: nice pickup today . anyone who has followed AZN for a while know if USA or UK is lead market for this stock , IE after 2.30pm does AZN here react to movement of AZN in usa or the other way around ?? i think USA is lead market from price movements Read Full Thread Follow Reply
10/9/2021 11:41	hjs: AZN has gone down as a result of their "Vaccine Booster" statement. Market will always react to any news to mark the share price up or down! this is my view. Read Full Thread Follow Reply
16/8/2021 10:49	beckers2008: Catching Up, well it is summer! 12/08/2021. Analysts at JP Morgan resumed their coverage of AstraZeneca at 'overweight', telling clients they saw a "re-rating opportunity". Indeed, with approximately 20% upside now on offer, JP Morgan also named the shares its UK large-cap top-pick. The company's share price, with an implied core price-to-earnings multiple of 15.5 and 13.5 times' for 2022 and 2023, was failing to reflect the company's superior growth outlook. "We see Astra's sector discount unwinding, as the Alexion acquisition demonstrates continued strong top-line growth, coupled with significant operating margin expansion and increased free cash flow generation," they added. That was on top of a "number" of upcoming pipeline catalysts that the broker said could drive long-term upgrades and multiple expansion. On their 10,000.0p target price, Astra would merely re-rate to a 2023 sector multiple, JP Morgan said. Among those potential catalysts were phase III data from Lynparza's PROpel front line Prostate cancer trial, ALXN1840 for Wilson's disease and phase III data for Enhertu DESTINY-04 for HER2 intermediate/low breast cancer. The former two dats sets were expected in the back half of 2021 and the latter in the front half of 2022. Read Full Thread Follow Reply
01/8/2021 09:09	waldron: CAMBRIDGE, Britain (AP) _ Astrazeneca PLC (AZN) on Thursday reported second-quarter profit of $550 million. The Cambridge, Britain-based company said it had profit of 21 cents per share. Earnings, adjusted for non-recurring costs, came to 45 cents per share. The pharmaceutical posted revenue of $8.22 billion in the period. Astrazeneca shares have increased 14% since the beginning of the year. The stock has climbed almost 1% in the last 12 months. This story was generated by Automated Insights (Http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AZN at Https://www.zacks.com/ap/AZN Read Full Thread Follow Reply
29/6/2021 10:44	philanderer: Drug breakthroughs to drive AstraZeneca, says Berenberg Breast cancer drug Enhertu is expected to provide further upside in AstraZeneca (AZN) shares, says broker Berenberg. Analyst Luisa Hector retained her ‘buy’ recommendation and £95 target price on the shares, which closed up 2%, or 167p, at £86.66 on Monday. Hector said the share price had ‘largely recovered from its winter woes when the company’s Covid-19 vaccine and the proposed Alexion acquisition led to downward pressure’. She is expecting AstraZeneca to continue delivering returns on its research and development programme, in particular the investment in Enhertu, a medicine used to treat breast cancer that has spread to other parts of the body or cannot be removed by surgery. ‘Positive data readouts in the second half from pipeline assets such as Enhertu should drive further upside in the AstraZeneca share price as probabilities of success increase and sales are subject to upward revisions,’ she said. HTTPS://citywire.co.uk/funds-insider/news/expert-view-astrazeneca-jd-sports-petrofac-greggs-and-alpha-financial/a1524218?section=funds-insider&_ga=2.33020406.917469266.1624959738-1068178417.1624959738#i=2 Read Full Thread Follow Reply
09/6/2021 19:53	arja: bad news announcement and AZN share price rockets - hard to understand the market at times ! Read Full Thread Follow Reply
04/5/2021 10:36	stutes: I note how Alexion adr is around $170 level - below bid price. I don't buy into the recent increase while AZN share price remains below £85 to £100 range. Alexion needs AZN's cash to fund future r&d - time to renegotiate the bid price ? Read Full Thread Follow Reply

Astrazeneca share price data is direct from the London Stock Exchange

Advertise Here

Your Recent History

LSE

AZN

Astrazenec..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US

P: V: D:20211027 13:08:49